Skip to main content

Table 1 Characteristics of individual trials included in the meta-analysis

From: 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials

Author Year Country Study type Study design Cases Age (year) Female (%) Cancer (%) Treatment QMG CMAP
McEvoy 1989 USA RCT Cross-over 12 34–75 8(66.7 %) 7(58.3 %) 3,4-DAP N/A CMAP
Sanders 2000 USA RCT Parallel 26 41–68 15(57.7 %) 10(38.5 %) 3,4-DAP QMG CMAP
Oh 2009 USA RCT Cross-over 6 25–75 1(16.7) 2(33.3 %) 3,4-DAP QMG CMAP
Wirtz 2009 Netherlands RCT Cross-over 9 33–73 4(44.4 %) N/A 3,4-DAP N/A CMAP
Oh 2016 USA RCT Parallel 36 21–88 23(63.9 %) 6(16.7 %) 3,4-DAP QMG CMAP
Shieh 2019 USA RCT Parallel 26 31–75 16(61.5 %) 6(23.1 %) 3,4-DAP QMG N/A
  1. N/A without data, QMG quantitative myasthenia gravis, CMAP compound muscle action potentials